Icon

RECLAST (nda021817)- (EQ 5MG BASE/100ML)

ZOLEDRONIC ACID SANDOZ
EQ 5MG BASE/100ML
Yes No
2028-Aug-05 Expired
None None
None No
Reclast is a bisphosphonate indicated for: • Treatment and prevention of postmenopausal osteoporosis • Treatment to increase bone mass in men with osteoporosis • Treatment and prevention of glucocorticoid-induced osteoporosis • Treatment of Paget’s disease of bone in men and women.
12 2 8
Total Other Developers None
Drugs with Suitability No
EQ 5MG BASE/100ML ** ** - - 4
NDA Sales Available Total Generic Sales Available
Yes 7
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ** ****** **** *** ***** ****** ******* *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***
****** ** ****** **** *** ***** ****** ******* *********** **** **: **-**, **, **, **-**, **. **. ***, ***, *** & ***, ***** ***, *****, ************ *******, ********** ******, ********** ********, *********, ********* ******, ***** (***) ***
****** ***** **** *** ***** ************ ******* *********** (***), **** **. ***-*, *********** ****** **** ****, ********** ****, ****** *****, *********, ********* ******, ***** (***) ***
****** ***** ***** ****** ******* *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***
****** ***** ***** ****** ******* *********** **** **: **-**, **, **, **-**, **. **. ***, ***, *** & ***, ***** ***, *****, ************ *******, ********** ******, ********** ********, *********, ********* ******, ***** (***) ***
****** ***** **** *** ***** ************ ******* *********** (***), **** **. ***-*, *********** ****** **** ****, ********** ****, ****** *****, *********, ********* ******, ***** (***) ***
****** ***** ****** ******** *.*. *** *********** ******* ********* ********** ****, ****** *****, ********, ********* (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-***, **** **: *, ** ** **, ***, ** ** **, ****, *****, ***, ************ *******, ********** ******, **********, ********* ******, ***** (***) ***
****** ***** ****** *** ***** ****** ******* *** *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***
****** ***** ****** *** ***** ****** ******* *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***
****** ******** ******* ****-****** *********** ************** **.,***. (*** ****) *********** **, ** ***** ****, ******* **** *** *** ********** *********** **** ******* ******, *******, ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.